ANALGESIA AFTER OPERATION: A controlled comparison of meptazinol, pentazocine and pethidine

Paymaster, N. J.

doi:10.1093/bja/49.11.1139

Cited by 28 publications

(17 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Meptazinol was found to produce a negligible effect on respiration in animals when compared with opiates and pentazocine (Stephens et al, 1978). Observations in normal human volunteers (Jordan et al, 1979) and patients (Verschraegen, 1976;Paymaster, 1977) confirm this favourable result. Meptazinol undergoes hepatic glucuronidation as opposed to N-demethylation and would not be expected to be metabolised as differently in mother and infant as is pethidine.…”

mentioning

confidence: 91%

Preliminary Experience of the Use of Meptazinol as an Obstetric Analgesic

Jackson¹,

Robson

1980

BJOG

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 91%

Preliminary Experience of the Use of Meptazinol as an Obstetric Analgesic

Jackson¹,

Robson

1980

BJOG

View full text Add to dashboard Cite

show abstract

“…There was a trend towards an increased volume of distribution in the patients with liver disease but this failed to reach statistical significance (control=303±32 1; NCLD=385+43 1; cirrhotic=402±36 1). There was no differences in the total plasma clearance of meptazinol between the groups (control=83± 10 following an oral dose of200 mg ofmeptazinol in control (n= 7), non-cirrhotic liver disease (NCLD) (n=8) and cirrhoticpatients (n=8). 12 …”

Section: Meptazinoi Kineticsmentioning

confidence: 97%

Enhanced oral bioavailability of meptazinol in cirrhosis.

Birnie¹,

Thompson²,

Murray³

et al. 1987

Gut

View full text Add to dashboard Cite

SUMMARY Kinetic analysis was carried out after single intravenous (25 mg) and oral (20() mg) doses of the novel partial opioid agonist meptazinol (Meptid) in patients with non-cirrhotic liver disease (NCLD) and biopsy proven cirrhosis. Comparison was made with a group of patients with normal hepatic function. Elimination half-lives after the intravenous dose were slightly prolonged in the cirrhotics (n= 10; 4 2+0*6 h) compared with the control (n=8; 2.7±0+2 h: p<()05) and NCLD (n=8; 3*2±0*5 h) groups. There was no significant difference in meptazinol plasma clearance between the groups (cirrhotics=72±8 1/h; NCLD=89±9 1/h; control=83± 10 1/h). After the oral dose, seven of 15 cirrhotic patients vomited but only one patient in each of the other groups was unable to tolerate the drug (p=006). This may be explained by very much higher peak meptazinol concentrations in the cirrhotic (n=8; 184±37 ng/ml, p<0-01) and NCLD (n=8; 131±38 ng/ml, p<0.05) patients than those of the controls (n=7; 53+12 ng/ml) reflecting a mean four-fold and two-fold increase in oral bioavailability respectively (cirrhotics: n=-; 27.9+5 3%/: p<0(001; NCLD: n=7; 13 7+3 9% p<005; controls: n=7; 6 5±133%). There was no evidence of accumulation after chronic dosing with 200 mg meptazinol four times daily for 13 doses in seven control, seven NCLD and six cirrhotic patients. There were no detectable differences in psychomotor function measured objectively using the Leeds Psychomotor Tester or subjectively by linear analogue scoring between the groups in all three parts of the study. The oral use of meptazinol in patients with chronic liver disease is associated more with the development of nausea and vomiting rather than excessive sedation. These data suggest that dosage reduction in cirrhotic patients is advisable particularly if the drug is taken by mouth.

show abstract

“…Meptazinol is a novel benzomorphan compound with partial opiate-antagonist properties which has been shown to be equivalent in analgesic potency at a dose of 100 mg to pethidine 100 mg (Paymaster, 1977; A. Hedges (personal communication); M. B. A. Jackson and P. J. Robson (personal communication), papaveretum 20 mg (Moyer, Miller and Aldridge, 1979) and pentazocine 60 mg (Paymaster, 1977), all drugs given i.m.…”

Section: Introductionmentioning

confidence: 99%

“…A. Jackson and P. J. Robson (personal communication), papaveretum 20 mg (Moyer, Miller and Aldridge, 1979) and pentazocine 60 mg (Paymaster, 1977), all drugs given i.m. It is free from anti-5-hydroxytryptamine and anti-cholinergic activity and in clinical trial has shown a low incidence of CNS side effects.…”

Section: Introductionmentioning

confidence: 99%

Double-blind crossover trial of oral meptazinol, pentazocine and placebo in the treatment of pain in the elderly

Pearce¹,

Robson²

1980

Postgraduate Medical Journal

View full text Add to dashboard Cite

SummaryIn a randomized, double-blind crossover trial in 30 elderly patients suffering from moderate to severe pain, the analgesic efficacy, tendency to produce mental confusion and side effect profile of meptazinol 100 mg orally were compared with those of pentazocine 25 mg orally and placebo.Both the active drugs produced significantly better analgesia than placebo but meptazinol also provided significantly better pain relief than pentazocine, whilst at the same time causing less mental confusion. Side effects were unremarkable.Meptazinol appears to be a better general purpose oral analgesic in this group of patients than pentazocine.

show abstract

ANALGESIA AFTER OPERATION: A controlled comparison of meptazinol, pentazocine and pethidine

Cited by 28 publications

References 8 publications

Preliminary Experience of the Use of Meptazinol as an Obstetric Analgesic

Preliminary Experience of the Use of Meptazinol as an Obstetric Analgesic

Enhanced oral bioavailability of meptazinol in cirrhosis.

Double-blind crossover trial of oral meptazinol, pentazocine and placebo in the treatment of pain in the elderly

Contact Info

Product

Resources

About